China Health Industries Stock Price To Sales
| CHHE Stock | USD 0.28 0.04 12.50% |
China Health Industries fundamentals help investors to digest information that contributes to China Health's financial success or failures. It also enables traders to predict the movement of China Pink Sheet. The fundamental analysis module provides a way to measure China Health's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to China Health pink sheet.
China |
China Health Industries Company Price To Sales Analysis
China Health's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current China Health Price To Sales | 1,000,000 X |
Most of China Health's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, China Health Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, China Health Industries has a Price To Sales of 1000 K times. This is much higher than that of the Personal Products sector and significantly higher than that of the Consumer Staples industry. The price to sales for all United States stocks is notably lower than that of the firm.
China Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses China Health's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of China Health could also be used in its relative valuation, which is a method of valuing China Health by comparing valuation metrics of similar companies.China Health is currently under evaluation in price to sales category among its peers.
China Fundamentals
| Return On Equity | -0.0186 | |||
| Return On Asset | -0.021 | |||
| Current Valuation | (25.17 M) | |||
| Shares Outstanding | 65.54 M | |||
| Shares Owned By Insiders | 31.29 % | |||
| Price To Earning | 4.02 X | |||
| Price To Book | 0.28 X | |||
| Price To Sales | 1,000,000 X | |||
| Revenue | 267 | |||
| Gross Profit | (1.48 K) | |||
| EBITDA | 479.53 K | |||
| Net Income | (353.95 K) | |||
| Cash And Equivalents | 44.79 M | |||
| Cash Per Share | 0.68 X | |||
| Total Debt | 6.76 M | |||
| Debt To Equity | 0.16 % | |||
| Current Ratio | 5.74 X | |||
| Book Value Per Share | 0.61 X | |||
| Cash Flow From Operations | 2.12 M | |||
| Earnings Per Share | (0.02) X | |||
| Number Of Employees | 45 | |||
| Beta | -9.15 | |||
| Market Capitalization | 10.5 M | |||
| Total Asset | 50.75 M | |||
| Retained Earnings | 32.92 M | |||
| Working Capital | 25.64 M | |||
| Current Asset | 31.62 M | |||
| Current Liabilities | 5.98 M | |||
| Z Score | 0.6 | |||
| Net Asset | 50.75 M |
About China Health Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze China Health Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of China Health using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of China Health Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in China Pink Sheet
China Health financial ratios help investors to determine whether China Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in China with respect to the benefits of owning China Health security.